Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Extensive Stage Small Cell Lung Cancer (ES-SCLC): early-phase trial registry
4 of 4 indexed Extensive Stage Small Cell Lung Cancer (ES-SCLC) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 4 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Extensive Stage Small Cell Lung Cancer (ES-SCLC): 4 US clinical trials tracked, 4 recruiting.
Extensive Stage Small Cell Lung Cancer (ES-SCLC) is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Bindu R Potugari, running 1 of these trials.
Enrollment posture brief
Registry condition extensive-stage-small-cell-lung-cancer-es-sclc
OPEN 4 | RECR 100% | LATE 1 | EARLY 3 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Extensive Stage Small Cell Lung Cancer (ES-SCLC) lists 4 open slots (100% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Extensive Stage Small Cell Lung Cancer (ES-SCLC) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Extensive Stage Small Cell Lung Cancer (ES-SCLC) is recruiting above its size-band peers.
4 of 4 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Gilead Sciences
NCT06801834
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
IDEAYA Biosciences
NCT05787587
SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer
Bindu R Potugari
NCT07339059
Iadademstat + SBRT With Atezo in ES-SCLC
Yale University
NCT07113691
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Extensive Stage Small Cell Lung Cancer (ES-SCLC) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Extensive Stage Small Cell Lung Cancer (ES-SCLC) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Extensive Stage Small Cell Lung Cancer (ES-SCLC) page
4 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Extensive Stage Small Cell Lung Cancer (ES-SCLC) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Bindu R Potugari sponsors the most Extensive Stage Small Cell Lung Cancer (ES-SCLC) trials on record, review their full trial history before evaluating a specific study. See Bindu R Potugari's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Extensive Stage Small Cell Lung Cancer (ES-SCLC) condition card totals 4 registered trials; most-linked intervention Atezolizumab; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.